| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | 2 | 2 | 1 | 50% | +2.5% | +2.5% |
| 3d | 2 | 2 | 1 | 50% | -1.6% | -1.6% |
| 1w | 2 | 2 | 0 | 0% | -1.2% | -1.2% |
| 1m | 2 | 2 | 1 | 50% | -4.0% | -4.0% |
| 3m | 1 | 1 | 1 | 100% | +22.1% | +22.1% |
| 6m | 0 | 0 | 0 | — | — | — |
| 1y | 0 | 0 | 0 | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
Compass Pathways will break through $17 and rally to $30 based on positive after-hours price action.
CMPS is positioned to become a leader in psychedelic medicine with COMP360 in Phase 3 for treatment-resistant depression and FDA breakthrough therapy designation. Approval would unlock a massive new treatment category, making $40 a realistic target that still undervalues the company's market opportunity.
End of results.